Research Article

You have full text access to this OnlineOpen article

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

  1. Pierre Quartier1,*,
  2. Pierre Taupin1,
  3. Franck Bourdeaut1,
  4. Irène Lemelle2,
  5. Pascal Pillet3,
  6. Michel Bost4,
  7. Jean Sibilia5,
  8. Isabelle Koné-Paut6,
  9. Sylvie Gandon-Laloum7,
  10. Marc LeBideau8,
  11. Brigitte Bader-Meunier9,
  12. Richard Mouy1,
  13. Marianne Debré1,
  14. Paul Landais1,
  15. Anne-Marie Prieur1

Article first published online: 3 APR 2003

DOI: 10.1002/art.10885

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 48, Issue 4, pages 1093–1101, April 2003

Additional Information

How to Cite

Quartier, P., Taupin, P., Bourdeaut, F., Lemelle, I., Pillet, P., Bost, M., Sibilia, J., Koné-Paut, I., Gandon-Laloum, S., LeBideau, M., Bader-Meunier, B., Mouy, R., Debré, M., Landais, P. and Prieur, A.-M. (2003), Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis & Rheumatism, 48: 1093–1101. doi: 10.1002/art.10885

Author Information

  1. 1

    Hôpital Necker-Enfants Malades, Paris, France

  2. 2

    Centre Hospitalo-Universitaire de Nancy, Nancy, France

  3. 3

    Hôpital Pellegrin, Centre Hospitalo-Universitaire de Bordeaux, Bordeaux, France

  4. 4

    Centre Hospitalier Général de Grenoble, Grenoble, France

  5. 5

    Centre Hospitalo-Universitaire de Strasbourg, Strasbourg, France

  6. 6

    Hôpital Nord, Marseilles, France

  7. 7

    Centre Hospitalier Général de Caen, Caen, France

  8. 8

    Hôpital de Saint Nazaire, Saint Nazaire, France

  9. 9

    Centre Hospitalo-Universitaire du Kremlin-Bicêtre, Kremlin-Bicêtre, France

*Unité d'Immuno-Hématologie et Rhumatologie pédiatrique, Hôpital Necker-Enfants Malades 149, rue de Sèvres, 75 743 Paris Cedex 15, France

Publication History

  1. Issue published online: 3 APR 2003
  2. Article first published online: 3 APR 2003
  3. Manuscript Accepted: 3 JAN 2003
  4. Manuscript Received: 29 MAR 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (97K)

REFERENCES

  • 1
    Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25: 1991–4.
  • 2
    Ansell BM. Prognosis in juvenile arthritis. Adv Exp Med Biol 1999; 455: 27–33.
  • 3
    Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992; 326: 1043–9.
  • 4
    Reiff A, Shaham B, Wood BP, Bernstein BH, Stanley P, Szer IS. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 113–8.
  • 5
    Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000; 43: 1849–57.
    Direct Link:
  • 6
    Halle F, Prieur AM. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol 1991; 9: 297–302.
  • 7
    Ravelli A, Viola S, Migliavacca D, Ruperto N, Pistorio A, Martini A. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatr 1999; 135: 316–20.
  • 8
    Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238–44.
  • 9
    Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763–9.
  • 10
    Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659–62.
  • 11
    Pouchot J, Ruperto N, Lemelle I, Sommelet D, Grouteau E, David L, et al. The French version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19 (4 Suppl 23 ): S60–5.
  • 12
    Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202–9.
  • 13
    Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121–30.
  • 14
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9.
  • 15
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93.
  • 16
    Kietz DA, Pepmueller PH, Moore TL. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J Rheumatol 2001; 28: 360–2.
  • 17
    Schmeling H, Mathony K, John V, Keysser G, Burdach S, Horneff G. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis 2001; 60: 410–2.
  • 18
    Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001; 76: 653–6.
  • 19
    Nunez Martinez O, Ripoll Noiseux C, Carneros Martin JA, Gonzalez Lara V, Gregorio Maranon HG. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol 2001; 96: 1665–6.
  • 20
    Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001; 45: 252–7.
    Direct Link:
  • 21
    Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti–tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862–9.
    Direct Link:
  • 22
    Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000; 137: 192–6.
  • 23
    Bleumink GS, ter Borg EJ, Ramselaar CG, Ch Stricker BH. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2001; 40: 1317–9.
  • 24
    Bloom BJ. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43: 2606–8.
    Direct Link:
  • 25
    Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999; 131: 634.
  • 26
    Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000; 27: 2041–4.
  • 27
    Skytta E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2000; 18: 533–4.
  • 28
    Kekow J, Welte T, Kellner U, Pap T. Development of rheumatoid nodules during anti–tumor necrosis factor α therapy with etanercept. Arthritis Rheum 2002; 46: 843–4.
    Direct Link:
  • 29
    Russell E, Zeihen M, Wergin S, Litton T. Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays. Arthritis Rheum 2000; 43: 944.
    Direct Link:
  • 30
    Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443–50.
    Direct Link:
  • 31
    Ten Cate R, van Suijlekom-Smit LW, Brinkman DM, Bekkering WP, Jansen-van Wijngaarden CJ, Vossen JM. Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2002; 41: 228–9.
  • 32
    Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002; 46: 1171–6.
    Direct Link:
  • 33
    Ravelli A, Ramenghi B, Di Fuccia G, Ruperto N, Zonta L, Martini A. Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. Acta Paediatr 1994; 83: 428–32.
    Direct Link:
  • 34
    Takei S, Groh D, Bernstein B, Shaham B, Gallagher K, Reiff A. Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J Rheumatol 2001; 28: 1677–80.
  • 35
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594–602.
View Full Article (HTML) Get PDF (97K)